University of Pittsburgh, UPMC play role in Moderna Covid-19 vaccine trials

PITTSBURGH — When Moderna’s Covid-19 vaccine gets to the point where it’s being administered, Pittsburgh will once again have played a role in helping to ease a global health crisis.

That’s because the University of Pittsburgh and UPMC’s Pittsburgh Vaccine Clinical Trials Unit at UPMC Children’s Hospital of Pittsburgh have been a clinical trial site for the Moderna and two other Covid-19 vaccines that are in earlier stages of development. About 250 people from the Pittsburgh region have either gotten the two-shot Moderna vaccine or placebos as part of the Phase III clinical trial.

Moderna on Monday provided an interim analysis of its Phase III trial that showed a vaccine efficacy rate of 94.5% among more than 30,000 people who participated in the study in the U.S. That, along with an early 90% effectiveness rate reported last week for the Pfizer Inc. study, buoyed hopes that the vaccines would be a significant weapon in the global fight against Covid-19.

Read more from our news partners at the Pittsburgh Business Times.

Comments on this article